BRIEF published on 04/04/2025 at 14:05, 8 months ago Oxurion General Meeting Postponed General Meeting Biopharmaceuticals Report Ophthalmic Therapies Oxurion
PRESS RELEASE published on 04/04/2025 at 14:00, 8 months ago Postponement Annual Shareholders Meeting Oxurion NV postponed its Annual Shareholders Meeting to May 13, 2025, due to pending annual accounts. The biopharmaceutical company, focused on ophthalmic therapies, is based in Leuven, Belgium Biopharmaceutical Annual Shareholders Meeting Postponed Ophthalmic Therapies Oxurion NV
BRIEF published on 04/02/2025 at 18:05, 8 months 2 days ago Oxurion Receives Transparency Notification from Atlas Special Opportunities II LLC Actions Transparency Atlas Special Opportunities Oxurion Biopharmacy
PRESS RELEASE published on 04/02/2025 at 18:00, 8 months 2 days ago Oxurion Receives Transparency Notification from Atlas Special Opportunities II LLC Oxurion NV, a biopharmaceutical company, received a transparency notification from Atlas Special Opportunities II, LLC regarding shareholding threshold crossing under Belgian legislation Transparency Notification Shareholding Threshold Oxurion NV Belgian Legislation Atlas Special Opportunities II LLC
BRIEF published on 03/27/2025 at 18:05, 8 months 8 days ago Oxurion receives adjusted transparency notification Transparency Notification Shareholding Oxurion Atlas Special Opportunities II Brussels Stock Exchange
PRESS RELEASE published on 03/27/2025 at 18:00, 8 months 8 days ago Oxurion Receives Amended Transparency Notification from Atlas Special Opportunities II LLC Oxurion NV received an amended transparency notification from Atlas Special Opportunities II, LLC regarding the sale of voting securities. This press release replaces the one from March 18, 2025 Transparency Notification Euronext Brussels Oxurion NV Retinal Disease Therapies Atlas Special Opportunities II
BRIEF published on 03/24/2025 at 18:05, 8 months 11 days ago Oxurion Announces Capital Increase Following Convertible Bond Conversion Convertible Bonds Capital Increase Atlas Special Opportunities Ophthalmic Therapies Oxurion
PRESS RELEASE published on 03/24/2025 at 18:00, 8 months 11 days ago Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas Atlas Special Opportunities, LLC converts bonds in Oxurion, resulting in EUR 150,000 capital increase. Oxurion focuses on developing therapeutics for vision care Capital Increase Therapeutics Vision Care Atlas Special Opportunities LLC Oxurion
BRIEF published on 03/18/2025 at 18:35, 8 months 17 days ago Oxurion Signs Letter of Intent for Acquisition of Biometrics-Focused CRO Regulatory Compliance Oxurion Acquisition Biometrics CRO Clinical Data Management ECRF Platform
PRESS RELEASE published on 03/18/2025 at 18:30, 8 months 17 days ago Oxurion signs a letter of intent for the planned acquisition of a biometrics-focused CRO Oxurion NV plans to acquire majority stake in a specialized CRO for clinical data management. Strategic move aligns with company's expansion strategy. Transaction valued at €650,000 Acquisition CRO Biometric Analysis Oxurion NV Clinical Data Management
Published on 12/05/2025 at 02:35, 7 hours 35 minutes ago Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 01:00, 9 hours 10 minutes ago BEACN Closes First Tranche of Non-Brokered Private Placement
Published on 12/04/2025 at 23:05, 11 hours 5 minutes ago BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Published on 12/04/2025 at 23:00, 11 hours 10 minutes ago NXT Energy Solutions Completes Data Acquisition for SFD Survey
Published on 12/05/2025 at 09:40, 30 minutes ago Chery Partners with 2025 Asian Youth Para Games, Taking Center Stage in Global Sports with Passion and Aspiration
Published on 12/05/2025 at 09:30, 40 minutes ago REPLOID Group AG: Exhibitor at the BIOGAS Convention & Trade Fair in Nuremberg, Germany
Published on 12/05/2025 at 09:05, 1 hour 5 minutes ago Transforming Football: IBM and Bayer 04 Leverkusen Use AI for Superior Game Analysis
Published on 12/05/2025 at 09:00, 1 hour 9 minutes ago Original-Research: DEMIRE AG (von NuWays AG): BUY
Published on 12/05/2025 at 08:45, 1 hour 25 minutes ago Air Liquide to expand and electrify its oxygen facility in Shaanxi, supporting China’s commitment to decarbonize its industry
Published on 12/04/2025 at 18:00, 16 hours 10 minutes ago Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Published on 12/04/2025 at 17:45, 16 hours 25 minutes ago MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
Published on 12/04/2025 at 17:44, 16 hours 26 minutes ago Net profit attributable to owners of the parent up by 63% to €122 million, driven by business resilience and the improvement in Elior's contribution
Published on 12/04/2025 at 07:01, 1 day 3 hours ago bioMérieux launches leading endocrinology testing offer dedicated to enhancing equine health
